Q BioMed, Jubilant Radiopharma Enter Commercial Pact

Q BioMed Inc. has entered into an exclusive distribution agreement for its non-opioid metastatic cancer pallion drug, Strontium-89 Chloride Injection USP (Strontium-89)/Metastron, with Jubilant Radiopharma for the U.S. market.  Jubilant Radiopharma specializes in nuclear medicine focused on developing, manufacturing, commercializing and distributing high quality and sustainable diagnostic and therapeutic agents on a global scale.
 
Strontium-89 is an FDA-approved non-opioid radiopharmaceutical indicated for the treatment of painful skeletal metastases caused by cancer. The product is administered intravenously once every three months as an alternative to opioid analgesics and plays a critical role in the treatment of metastatic bone pain.
 
Once the FDA approves Q BioMed as the contract manufacturer, the large population of potential Strontium-89 patients in the U.S. will again have access the drug. Denis Corin, CEO of Q BioMed, said, “Our partnership with Jubilant Radiopharma is an essential component of our upcoming commercial launch and means that we’ll be able to reach providers and patients across the country through a scalable, highly-efficient program, thereby re-establishing supply of this life-changing therapy to those suffering from this debilitating pain.”
 
Jubilant Radiopharma operates the second-largest commercial radiopharmacy network in the U.S. Pramod Yadav, CEO, Jubilant Pharma Limited said, “Jubilant Radiopharma is committed to improving lives through Nuclear Medicine by providing healthcare professionals access to high quality, FDA approved products that enable better patient outcomes. We are pleased to partner with Q BioMed to bring this important cancer pain therapy to healthcare providers and patients who so desperately need choices in cancer pain treatment.”
 
Q BioMed and Jubilant Radiopharma intend to announce further details regarding availability of Strontium-89 later this year.